CN115052597B - 抗生素组合疗法 - Google Patents

抗生素组合疗法 Download PDF

Info

Publication number
CN115052597B
CN115052597B CN202080077930.0A CN202080077930A CN115052597B CN 115052597 B CN115052597 B CN 115052597B CN 202080077930 A CN202080077930 A CN 202080077930A CN 115052597 B CN115052597 B CN 115052597B
Authority
CN
China
Prior art keywords
rifabutin
colistin
antibiotics
antibiotic
acinetobacter baumannii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080077930.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115052597A (zh
Inventor
V·特雷博斯
C·凯默尔
G·E·戴尔
S·洛基乌罗
M·吉特青格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioversys AG
Original Assignee
Bioversys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioversys AG filed Critical Bioversys AG
Priority to CN202511016208.7A priority Critical patent/CN120860031A/zh
Publication of CN115052597A publication Critical patent/CN115052597A/zh
Application granted granted Critical
Publication of CN115052597B publication Critical patent/CN115052597B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080077930.0A 2019-09-12 2020-08-03 抗生素组合疗法 Active CN115052597B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511016208.7A CN120860031A (zh) 2019-09-12 2020-08-03 抗生素组合疗法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US62/899,257 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US62/902,019 2019-09-18
US201962941160P 2019-11-27 2019-11-27
US62/941,160 2019-11-27
US202062977659P 2020-02-17 2020-02-17
US62/977,659 2020-02-17
PCT/IB2020/000645 WO2021048610A1 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511016208.7A Division CN120860031A (zh) 2019-09-12 2020-08-03 抗生素组合疗法

Publications (2)

Publication Number Publication Date
CN115052597A CN115052597A (zh) 2022-09-13
CN115052597B true CN115052597B (zh) 2025-07-08

Family

ID=72432957

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080077930.0A Active CN115052597B (zh) 2019-09-12 2020-08-03 抗生素组合疗法
CN202511016208.7A Pending CN120860031A (zh) 2019-09-12 2020-08-03 抗生素组合疗法
CN202080077348.4A Pending CN114980889A (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202511016208.7A Pending CN120860031A (zh) 2019-09-12 2020-08-03 抗生素组合疗法
CN202080077348.4A Pending CN114980889A (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物

Country Status (17)

Country Link
US (6) US11207305B2 (https=)
EP (3) EP4028001B1 (https=)
JP (4) JP7769605B2 (https=)
KR (1) KR20220103698A (https=)
CN (3) CN115052597B (https=)
AU (2) AU2020344214B2 (https=)
BR (2) BR112022004672A2 (https=)
CA (2) CA3154317A1 (https=)
ES (1) ES2982067T3 (https=)
HR (1) HRP20240818T1 (https=)
HU (1) HUE066936T2 (https=)
MX (1) MX2022003077A (https=)
PH (1) PH12022550610A1 (https=)
PL (1) PL4028001T3 (https=)
RS (1) RS65681B1 (https=)
SM (1) SMT202400250T1 (https=)
WO (2) WO2021048610A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) * 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016013986A1 (en) * 2014-07-25 2016-01-28 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
WO2018035183A1 (en) * 2016-08-16 2018-02-22 University Of Rochester Pharmaceutical composition containing polymyxin b/trimethoprim based therapeutics

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645508B1 (en) * 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN101362067A (zh) * 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
PT2247291T (pt) * 2008-02-08 2019-02-01 Red Hill Biopharma Ltd Métodos e composições para tratamento de doença inflamatória do intestino
MY158809A (en) 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
US10064858B2 (en) * 2011-01-31 2018-09-04 The United States Of America, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
CN102178604B (zh) 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
RU2472512C1 (ru) * 2011-12-06 2013-01-20 Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" Противотуберкулезная композиция и способ ее получения
CN107148479A (zh) * 2014-09-04 2017-09-08 赛拉诺斯股份有限公司 病原体和抗微生物剂抗性检测
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
EP3291798A4 (en) * 2015-05-04 2019-01-16 Gufic Biosciences Limited FREEZE-DRIED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND METHOD FOR THE PRODUCTION THEREOF
JP2020506236A (ja) 2017-02-07 2020-02-27 エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ 長期間持続するオートファジー誘発のための同位体増強アンブロキソール
US11701346B2 (en) * 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016013986A1 (en) * 2014-07-25 2016-01-28 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
WO2018035183A1 (en) * 2016-08-16 2018-02-22 University Of Rochester Pharmaceutical composition containing polymyxin b/trimethoprim based therapeutics

Also Published As

Publication number Publication date
HRP20240818T1 (hr) 2024-10-11
EP4028001B1 (en) 2024-04-10
WO2021048610A1 (en) 2021-03-18
AU2020347536A1 (en) 2022-04-14
JP2026016690A (ja) 2026-02-03
KR20220103698A (ko) 2022-07-22
US20250281469A1 (en) 2025-09-11
PL4028001T3 (pl) 2024-07-22
AU2020344214A1 (en) 2022-04-21
US11833139B2 (en) 2023-12-05
CN120860031A (zh) 2025-10-31
JP2022548252A (ja) 2022-11-17
US20220184048A1 (en) 2022-06-16
BR112022004672A2 (pt) 2022-06-07
EP4028001C0 (en) 2024-04-10
US11351158B2 (en) 2022-06-07
CN114980889A (zh) 2022-08-30
ES2982067T3 (es) 2024-10-14
WO2021048611A1 (en) 2021-03-18
JP2025176113A (ja) 2025-12-03
BR112022004645A2 (pt) 2022-06-21
EP4028000A1 (en) 2022-07-20
SMT202400250T1 (it) 2024-07-09
AU2020347536B2 (en) 2025-09-25
JP7804570B2 (ja) 2026-01-22
MX2022003077A (es) 2022-07-11
JP7769605B2 (ja) 2025-11-13
US11207305B2 (en) 2021-12-28
CA3154317A1 (en) 2021-03-18
RS65681B1 (sr) 2024-07-31
US20230132691A1 (en) 2023-05-04
US11766425B2 (en) 2023-09-26
US12257241B2 (en) 2025-03-25
CN115052597A (zh) 2022-09-13
US20210077472A1 (en) 2021-03-18
EP4420673A2 (en) 2024-08-28
CA3154129A1 (en) 2021-03-18
US20210077471A1 (en) 2021-03-18
JP2022551228A (ja) 2022-12-08
EP4420673A3 (en) 2024-11-06
AU2020344214B2 (en) 2026-01-22
HUE066936T2 (hu) 2024-09-28
PH12022550610A1 (en) 2023-03-13
US20240041845A1 (en) 2024-02-08
EP4028001A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
Hagel et al. Perioperative antibiotic prophylaxis and antimicrobial therapy of intra-abdominal infections
JP5782615B2 (ja) オリタバンシンの単回用量を用いる治療の方法
US12370184B2 (en) Antibiotic combination therapies
JP2025176113A (ja) 抗生物質併用療法
Metallidis et al. Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty
ES2690725T3 (es) Composiciones que comprenden cefepima y tazobactam
US20230364065A1 (en) Antibiotic combination therapies
Shamaei-Tousi et al. RESULTS FROM A PHASE 2 CLINICAL TRIAL FOR TREATMENT OF BONE AND JOINT INFECTIONS WITH AFABICIN, A FIRST-IN-CLASS SELECTIVE ANTI-STAPHYLOCOCCAL ANTIBIOTIC
Inoshita et al. A randomized prospective study of oral levofloxacin vs intravenous flomoxef prophylaxis in postoperative infection after endoscopic sinus surgery
WO2011146255A1 (en) Combination therapy for the treatment of bacterial infections caused by acinetobacter baumannii
Wilson et al. A clinical trial of teicoplanin compared with a combination of flucloxacillin and tobramycin as antibiotic prophylaxis for cardiac surgery: the use of a scoring method to assess the incidence of wound infection
Zheng et al. Assessing morinidazole for surgical site infection in class III wounds prevention: a multi-centre, randomized, single-blind, parallel-controlled study
Suankratay et al. Effectiveness and Adverse Events of Generic and Original Imipenem/Cilastatin in Hospitalized Patients: The First Multicenter Non-Inferiority Study in Thailand
Hansen et al. Post-traumatic Acinetobacter baumannii Meningitis Following Penetrating Trauma: A Case Report
Nord Use of newer quinolones for the treatment of intraabdominal infections: Focus on clinafloxacin
Furlanut et al. Guidelines on Antibiotic Combination in ICU Patients
DuPont Overview of clinical experience of pefloxacin in gastrointestinal infections
HARIGANE et al. Short-duration Antimicrobial Prophylaxis is Recommended for Orthopedic Surgery in Patients with Rheumatoid Arthritis
Bassetti et al. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA)
Weinstein Chairman's summary
Johnson et al. In Vitro Activity of Tigecycline against Multi-Drug Resistant Acinetobacter from the TEST Program Worldwide
TAILOR et al. Activity of Doripenem (DOR) Against Molecularly Characterized AmpC and ESBL Producing Escherichia coli (EC) Including Strains with Reduced Susceptibility to Carbapenems (CRS) from Canadian Hospitals: CANWARD 2007-2010
Moreland Faropenem medoxomil reaches the CAP in RTIs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant